Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism
- 11 August 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Pediatric Nephrology
- Vol. 25 (4), 591-601
- https://doi.org/10.1007/s00467-009-1273-z
Abstract
There are a number of hypophosphatemic disorders due to renal phosphate wasting that cannot be explained by elevated levels of parathyroid hormone. The circulating factors responsible for the phosphaturia have been designated as phosphatonins. Studies of patients with tumor-induced osteomalacia and other genetic diseases of phosphate metabolism have resulted in the identification of a number of hormones that regulate phosphate homeostasis, including matrix extracellular phosphoglycoprotein (MEPE), secreted frizzled-related protein 4 (sFRP-4), dentin matrix protein 1 (DMP1), fibroblast growth factor 7 (FGF7), fibroblast growth factor 23 (FGF23), and Klotho. Our understanding of the actions of these hypophosphatemic peptides has been enhanced by studies in mice either overexpressing or not expressing these hormones. This review focuses on FGF23 since its regulation is disordered in diseases that affect children, such as X-linked hypophosphatemia, autosomal dominant and recessive hypophosphatemic rickets as well as chronic kidney disease. Recent studies have shown that FGF23 is unique among the FGFs in its requirement for Klotho for receptor activation. Here, we also discuss new potentially clinically important data pointing to the receptor(s) that mediate the binding and action of FGF23 and Klotho.Keywords
This publication has 111 references indexed in Scilit:
- FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1American Journal of Physiology-Renal Physiology, 2009
- Renal phosphate wasting due to tumor-induced osteomalacia: a frequently delayed diagnosisKidney International, 2009
- In vivo genetic evidence for klotho‐dependent, fibroblast growth factor 23 (Fgf23) ‐mediated regulation of systemic phosphate homeostasisThe FASEB Journal, 2008
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008
- A translocation causing increased α-Klotho level results in hypophosphatemic rickets and hyperparathyroidismProceedings of the National Academy of Sciences of the United States of America, 2008
- A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosisJCI Insight, 2007
- Genetic Ablation of Vitamin D Activation Pathway Reverses Biochemical and Skeletal Anomalies in Fgf-23-Null AnimalsThe American Journal of Pathology, 2006
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006
- Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolismNature Genetics, 2006
- FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate HomeostasisJournal of Bone and Mineral Research, 2004